AbbVie to Buy Cerevel Therapeutics for US$8.7 B to Bolster Neuroscience Portfolio
By Lucy Haggerty
Pharma Deals Review: Vol 2023 Issue 12 (Table of Contents)
Published: 13 Dec-2023
DOI: 10.3833/pdr.v2023.i12.2844 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Continuing its buying spree, AbbVie has agreed to acquire Cerevel Therapeutics for US$45 per share in cash, representing a total equity value of approximately US$8...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS